GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Chemed Corp (NYSE:CHE) » Definitions » Beneish M-Score
中文

Chemed (Chemed) Beneish M-Score : -2.35 (As of Apr. 25, 2024)


View and export this data going back to 1982. Start your Free Trial

What is Chemed Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.35 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Chemed's Beneish M-Score or its related term are showing as below:

CHE' s Beneish M-Score Range Over the Past 10 Years
Min: -3.19   Med: -2.61   Max: -2.18
Current: -2.35

During the past 13 years, the highest Beneish M-Score of Chemed was -2.18. The lowest was -3.19. And the median was -2.61.


Chemed Beneish M-Score Historical Data

The historical data trend for Chemed's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chemed Beneish M-Score Chart

Chemed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.66 -3.19 -2.79 -2.55 -2.35

Chemed Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.55 -2.15 -2.80 -2.25 -2.35

Competitive Comparison of Chemed's Beneish M-Score

For the Medical Care Facilities subindustry, Chemed's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chemed's Beneish M-Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Chemed's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Chemed's Beneish M-Score falls into.



Chemed Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Chemed for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.2276+0.528 * 1.0158+0.404 * 0.8676+0.892 * 1.0606+0.115 * 0.9637
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0385+4.679 * -0.037268-0.327 * 0.7134
=-2.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $182 Mil.
Revenue was 585.912 + 564.532 + 553.816 + 560.157 = $2,264 Mil.
Gross Profit was 227.566 + 202.174 + 179.623 + 189.452 = $799 Mil.
Total Current Assets was $501 Mil.
Total Assets was $1,668 Mil.
Property, Plant and Equipment(Net PPE) was $330 Mil.
Depreciation, Depletion and Amortization(DDA) was $61 Mil.
Selling, General, & Admin. Expense(SGA) was $395 Mil.
Total Current Liabilities was $312 Mil.
Long-Term Debt & Capital Lease Obligation was $101 Mil.
Net Income was 90.053 + 74.958 + 53.377 + 54.121 = $273 Mil.
Non Operating Income was 4.314 + 0.002 + -0.008 + 0.068 = $4 Mil.
Cash Flow from Operations was 108.563 + 28.927 + 132.317 + 60.492 = $330 Mil.
Total Receivables was $139 Mil.
Revenue was 546.654 + 526.472 + 531.288 + 530.549 = $2,135 Mil.
Gross Profit was 197.084 + 179.538 + 194.467 + 193.997 = $765 Mil.
Total Current Assets was $273 Mil.
Total Assets was $1,442 Mil.
Property, Plant and Equipment(Net PPE) was $335 Mil.
Depreciation, Depletion and Amortization(DDA) was $59 Mil.
Selling, General, & Admin. Expense(SGA) was $359 Mil.
Total Current Liabilities was $297 Mil.
Long-Term Debt & Capital Lease Obligation was $203 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(181.511 / 2264.417) / (139.408 / 2134.963)
=0.080158 / 0.065298
=1.2276

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(765.086 / 2134.963) / (798.815 / 2264.417)
=0.35836 / 0.352769
=1.0158

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (500.843 + 330.227) / 1668.095) / (1 - (272.612 + 335.376) / 1442.012)
=0.501785 / 0.578375
=0.8676

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2264.417 / 2134.963
=1.0606

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(59.172 / (59.172 + 335.376)) / (60.865 / (60.865 + 330.227))
=0.149974 / 0.155628
=0.9637

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(395.121 / 2264.417) / (358.727 / 2134.963)
=0.174491 / 0.168025
=1.0385

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((100.776 + 312.05) / 1668.095) / ((203.013 + 297.205) / 1442.012)
=0.247484 / 0.346889
=0.7134

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(272.509 - 4.376 - 330.299) / 1668.095
=-0.037268

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Chemed has a M-score of -2.35 suggests that the company is unlikely to be a manipulator.


Chemed (Chemed) Business Description

Traded in Other Exchanges
Address
255 East Fifth Street, Suite 2600, Cincinnati, OH, USA, 45202-4726
Chemed Corp operates subsidiaries in two main segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue. It provides hospice and palliative-care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The vast majority of the segment's revenue is received from the Medicare and Medicaid reimbursement programs. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers. Chemed generates the majority of its revenue from business in the United States.
Executives
Kevin J Mcnamara director, officer: president & ceo 2500 CHEMED CENTER, 255 EAST FIFTH ST, CINCINNATI OH 45202
Spencer S Lee officer: vice president 2500 CHEMED CENTER, 255 EAST FIFTH ST, CINCINNATI OH 45202
David Patrick Williams officer: Vice President & CFO
Nicholas Michael Westfall officer: Executive Vice President 8035 PEREGRINE LANE, CINCINNATI OH 45243
Patrick P Grace director 1100 PARK AVE, APT 15C, NEW YORK NY 10128
Eileen P Mccarthy director 3515 78TH STREET, #2, JACKSON HEIGHTS NY 11372
Michael D Witzeman officer: vice president and controller 255 E 5TH STREET, SUITE 2600, CINCINNATI OH 45202
Mount John Meredith Jr. director 2906 MABRY ROAD NE, ATLANTA GA 30319
Donald E Saunders director 306 MIANI TRAIL, OXFORD OH 45056
Christopher J Heaney director 101 S. FORT LAUDERDALE BEACH BLVD., APARTMENT 1602, FORT LAUDERDALE FL 33316
Ron Delyons director 2692 MADISON ROAD, SUITE N1-313, CINCINNATI OH 45208
Naomi C Dallob officer: VP and Chief Legal Officer 255 EAST FIFTH STREET, SUITE 2600, CINCINNATI OH 45202
Thomas C Hutton director, officer: vice president ONE ROCKEFELLER PLAZA, STE 1510, NEW YORK NY 10020
Walsh George J Iii director ONE CHASE MANHATTAN PLAZA, NEW YORK NY 10005
Andrea R Lindell director